By IDSE News Staff
A clinical trial testing infusions of combination antibodies in people living with HIV has begun at the National Institute of Allergy and Infectious Diseases.
The early-phase clinical trial will evaluate whether periodic infusions of two highly potent, HIV-specific broadly neutralizing antibodies (bNAbs)—3BNC117 and 10-1074—are safe in people living with HIV. The study also will gather preliminary data on how effectively the bNAb infusions, delivered together every
SEPTEMBER 21, 2018